Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig. 6 h (r1c2)
Alasaadi DN et al. (2024)
|
Xla Wt + yap1 MO
NF18 (in situ hybridization)
|
|
|
|
Fig. 4 fg
Alasaadi DN et al. (2024)
|
Xla Wt + yap1 MO + BIO
NF16-17 (in situ hybridization)
|
|
|
|
Fig. 5 FG
Devotta A et al. (2023)
|
Xla wt + A71915 (npr1 antagonist)
NF15 (in situ hybridization)
|
|
|
|
Fig 2 FG
Devotta A et al. (2023)
|
Xla wt + AP-811 (npr3 antagonist)
NF15 (in situ hybridization)
|
|
|
|
Fig 6 Ar1 B
Devotta A et al. (2023)
|
Xla Wt + nppa MO
NF15 (in situ hybridization)
|
|
|
|
Fig 6 A:r3 BDE
Devotta A et al. (2023)
|
Xla Wt + nppc MO
NF15 (in situ hybridization)
|
|
|
|
Fig. 5 B:c2r1 CD
Devotta A et al. (2023)
|
Xla Wt + npr1 MO
NF15 (in situ hybridization)
|
|
|
|
Fig. 2 CD
Devotta A et al. (2023)
|
Xla Wt + npr3 MO
NF15 (in situ hybridization)
|
|
|
|
Fig. 3 A, F
Pandey A et al. (2023)
|
Xla Wt + adam11 MO (unilateral)
NF17-18 (in situ hybridization)
|
|
|
|
XB-PHENO-25425
Flach H et al. (2021)
|
Xla Wt + rbp1 MO1
NF16
|
|
|